| A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
|
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |
| A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: A joint pilot trial of the Nort |
|
Pediatric Blood & Cancer |
Aplastic Anemia, Pediatric |
| Acquired Aplastic Anemia Therapies: Immunosuppressive Therapy Versus Alternative Donor Hematopoietic Cell Transplantation |
|
Journal of Hematology |
Aplastic Anemia |
| Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS |
|
Current Hematologic Malignancy Report |
Myelodysplastic Syndromes (MDS) |
| Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
